Phase I safety and tolerability study of Acarovac Quattro

Trial Profile

Phase I safety and tolerability study of Acarovac Quattro

Planning
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs House dust mite allergy immunotherapy Allergy Therapeutics (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Feb 2017 According to an Allergy Therapeutics media release, company is planning to initiate Phase I studies (this and other trial 281897) at two different dose regimens. Both treatment regimens include a two-to-four week initial up-dosing phase but differ in the duration of the later maintenance phase. This trial is expected to last one year.
    • 14 Feb 2017 According to an Allergy Therapeutics media release, this trial has received Clinical Trial Application (CTA) approval in Spain.
    • 18 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top